AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
Key takeaways
- TEZSPIRE’s Phase III trial shows sustained, clinically meaningful benefits in EoE, supporting its future development and market potential.
- 470,000 U.S. patients with EoE
- five‑fold increase in prevalence since 2009
- week 24 primary endpoint
What happened
AstraZeneca and Amgen announced that their drug TEZSPIRE (tezepelumab‑ekko) met both co‑primary endpoints in the Phase III CROSSING trial for eosinophilic esophagitis (EoE), showing statistically significant and clinically meaningful improvements in histologic remission and dysphagia scores at week 24, with benefits lasting through week 52.
Why it matters
The data confirm TEZSPIRE’s efficacy in a large, difficult‑to‑treat patient group—over 470,000 Americans with EoE—providing a new therapeutic option where current treatments fail for nearly half of patients.
Short-term and longer-term
Short-term. Short‑term traders should watch for any immediate market reaction to the announcement, as the data may prompt a modest lift in AZN and AMGN shares.
Longer-term. Longer‑term investors should note that the positive Phase III results strengthen TEZSPIRE’s pipeline position in a sizable and growing EoE market, potentially expanding the drug’s commercial scope and supporting future…